BioLineRx Stock Jumps 14% on St. Jude Clinical Trial for Mitoxafortide

Seeking AlphaMay 30 13:54 ET

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise

CRISPR TherapeuticsMay 29 00:00 ET

The wave of US biopharmaceutical mergers and acquisitions has set off who will be the next potential target?

The Zhitong Finance App learned that Wells Fargo released its annual list of potential mergers and acquisitions in the biopharmaceutical industry, adding diet drug developers Viking Therapeutics (VKTX.US), gene editing company CRISPR Therapeutics (CRSP.US), and Intellia Therapeutics (NTLA.US) to the list of potential acquisition targets in 2024. The investment bank has identified 31 such companies in the biopharmaceutical small to medium cap sector, and these companies are highly or moderately suitable for the following large pharmaceutical companies

Zhitong FinanceMay 26 23:21 ET

Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo

Seeking AlphaMay 25 10:24 ET

It's Probably Less Likely That CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Will See A Huge Pay Rise This Year

Key Insights CRISPR Therapeutics will host its Annual General Meeting on 30th of May CEO Sam Kulkarni's total compensation includes salary of US$724.5k The total compensation is similar to the ave

Simply Wall StMay 24 08:13 ET

BofA Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $100

BofA Securities analyst Geoff Meacham maintains $CRISPR Therapeutics(CRSP.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 5

moomoo NewsMay 23 19:31 ET